Monday, 23 January 2017

Business Standard


Ø  RIL to raise $2.25 billion more via foreign borrowings

Ø  US investment visa to get costlier by Rs 5.4 crore

Ø  Double I-T exemption limit to Rs 5 lakh: EY

Ø  PhonePe accuses ICICI bank of 'scaring' customers

Ø  November IIP 'false positive', doesn't reflect reality: Crisil

Ø  Demonetisation puts probe agencies in a fix

Ø  Ruia family may lose control over Essar Steel



Ø  Demonetisation ruffles feathers of early birds

Ø  OMCs may recoup card charges at motor fuel outlets through price hikes

Ø  20 projects to cut costs, improve efficiency: Tata Motors

Ø  Note ban has negative impact on jobs, SMEs: survey

Ø  Restructured education loans not to be treated as NPAs: RBI

Ø  CCI imposes penalties on cement companies for bid-rigging, cartelization

Ø  Indian bonds best performers in Asia in 2016: Nomura


Mint

Ø  PHDCCI urges Jaitley to cut corporate tax rate to 25%

Ø  SEBI accepts Tata view on corporate governance issues raised by Mistry

Ø  FICCI for increasing domestic gas price 

Ø  FPIs pull out over Rs. 5,100 cr from capital market this month 

Ø  Amara Raja Batteries’ Q3 net profit falls 18%


Ø  Job opportunities to 1 crore youth by 2020: Labour minister

Ø  GM puts on hold investments on new products for India

Ø  Govt analyses cash deposits in last 10 days of demonetisation

Ø  United Spirits Q3 profit jumps over threefold to Rs148 crore

Ø  UltraTech Q3 profit rises 5.13% to Rs594.61 crore

Ø  GSPC looks at financial restructuring post ONGC deal

 Financial Chronicle

Ø  Weather models suggest resurfacing of El-Nino: Skymet

Ø  No fake currency in circulation post note-ban: Anil Bokil

Ø  Blame costly wars, not China, for poor state of US economy: Jack Ma

Ø  Steel companies seek removal of import duty, cess on coking coal


Ø  RBI apprised govt of DeMo consequences: Urjit

Ø  FinMin asks depts to avoid spending rush in March qtr

Ø  FRBM panel’s prescription suits govt plan to up spending

Ø  Patel not yet out of the House panel cross hairs

Ø  Trump’s drug cost concern an opportunity for Indian firms

No comments:

Post a Comment